Cromos Pharma, where the patients are

Decision Resources

Report: U.S. Alzheimer's imaging agent market will grow as reimbursement improves

Thursday, February 13, 2014 03:03 PM

The U.S. Alzheimer's imaging agent market will grow dramatically over the next 10 years, according to Decision Resources Group. Currently, Eli Lilly's Amyvid, launched in June 2013, is the only FDA-approved product available, but GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticalsare all poised to launch products in the U.S. in the next few years.

More... »

CRF Health eCOA webinar series

Decision Resources Group acquires Relay Technology Management

Wednesday, January 8, 2014 01:31 PM

Piramal Enterprises' information management subsidiary, Decision Resources Group, a research and advisory firm focusing on high-value healthcare insights and analytics, has acquired Relay Technology Management, a data analytics company focused on the life sciences industry.

More... »


Report: Pharma should factor medication adherence into drug development

Monday, December 2, 2013 10:34 AM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has a new strategic insights report that found in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process.

More... »

Report: use of biomarkers outside oncology trials increasing

Thursday, November 14, 2013 11:00 AM

Decision Resources, a research and advisory firm focusing on pharmaceutical and healthcare issues, found while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions and their use in clinical trials of drugs outside of oncology is building.

More... »

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Monday, October 28, 2013 02:22 PM

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

More... »

Report: Increase in Biopharma new product launches originating from in-licensing deals

Friday, October 18, 2013 01:51 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, reports that biopharma companies industry-wide are increasingly moving away from in-house research and toward acquisitive strategies to build their portfolios and grow sales. According to findings from the Strategic Insights report, the fraction of new product launches that originate from in-licensing has increased dramatically over the last decade. In 2012, 53% of new product launches were in-licensed during development, as compared to an average of 32% between 2003 and 2012.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

China’s type 2 diabetes market forecast to grow to $3.5 billion by 2017

Wednesday, August 14, 2013 01:20 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, forecasts the type 2 diabetes therapeutic market in China, the third largest after the U.S. and Japan, will grow 10% annually, reaching $3.5 billion in 2017. Fueling this expansion are the growing number of drug-treated patients and the increasing use of dipeptidyl peptidase-4 (DPP-IV) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and insulin analogues.

More... »

Piramal Healthcare to acquire Decision Resources Group

Thursday, May 17, 2012 10:04 AM

Piramal Healthcare, a pharmaceutical custom manufacturing company, has agreed to acquire Decision Resources Group (DRG), a healthcare information company of Burlington, Mass., from Providence Equity Partners for approximately $635 million.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs